FDA Targeting GDUFA Fee Scofflaws Again With Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Four warning letters this year have gone to companies that owe finished dosage form and active pharmaceutical ingredient facility fees.
You may also be interested in...
User Fee Program Six-Month Metrics
After six months under the new prescription drug, generic drug and biosimilar user fee programs, FDA has shown some progress in collecting the necessary fees and conducting sponsor meetings required under the new programs.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.